SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

DEAR DR. ROACH: I am a 70-year old woman with a prior history of asymptomatic atrial fibrillation (AFib). I’ve been in normal sinus rhythm since having two catheter ablations in 2018. I take Eliquis ...

In China, left atrial appendage (LAA) occlusion using the first-generation Watchman 2.5 device (Boston Scientific) is being performed with high procedural success plus low rates of periprocedural ...

Any leakage around a percutaneous left atrial appendage (LAA) implant, no matter how small, predicted strokes and other thrombotic events after the procedure, according to a retrospective study. In ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

A new study finds clinicians are shifting away from the FDA-approved combination of warfarin and aspirin after left atrial appendage occlusion (LAAO) with the Watchman device and that adverse events, ...

Please provide your email address to receive an email when new articles are posted on . In a real-world analysis of registry data, researchers also found that the Watchman FLX device (Boston ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 70-year old woman with a prior history of ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...